tradingkey.logo

MiMedx Group Inc

MDXG
查看詳細走勢圖
6.900USD
-0.180-2.54%
收盤 12/26, 16:00美東報價延遲15分鐘
1.02B總市值
24.93本益比TTM

MiMedx Group Inc

6.900
-0.180-2.54%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.54%

5天

-2.13%

1月

+0.29%

6月

+16.16%

今年開始到現在

-28.27%

1年

-26.52%

查看詳細走勢圖

TradingKey MiMedx Group Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

MiMedx Group Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名48/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價12.20。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

MiMedx Group Inc評分

相關信息

行業排名
48 / 404
全市場排名
133 / 4563
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
12.200
目標均價
+82.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

MiMedx Group Inc亮點

亮點風險
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
業績高增長
公司營業收入穩步增長,連續3年增長30.26%
估值高估
公司最新PE估值24.93,處於3年歷史高位
機構減倉
最新機構持股104.90M股,環比減少3.52%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉15.75K股

MiMedx Group Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

MiMedx Group Inc簡介

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
公司代碼MDXG
公司MiMedx Group Inc
CEOCapper (Joseph H)
網址https://mimedx.com/

常見問題

MiMedx Group Inc(MDXG)的當前股價是多少?

MiMedx Group Inc(MDXG)的當前股價是 6.900。

MiMedx Group Inc 的股票代碼是什麼?

MiMedx Group Inc的股票代碼是MDXG。

MiMedx Group Inc股票的52週最高點是多少?

MiMedx Group Inc股票的52週最高點是9.710。

MiMedx Group Inc股票的52週最低點是多少?

MiMedx Group Inc股票的52週最低點是5.790。

MiMedx Group Inc的市值是多少?

MiMedx Group Inc的市值是1.02B。

MiMedx Group Inc的淨利潤是多少?

MiMedx Group Inc的淨利潤為42.42M。

現在MiMedx Group Inc(MDXG)的股票是買入、持有還是賣出?

根據分析師評級,MiMedx Group Inc(MDXG)的總體評級為買入,目標價格為12.200。

MiMedx Group Inc(MDXG)股票的每股收益(EPS TTM)是多少

MiMedx Group Inc(MDXG)股票的每股收益(EPS TTM)是0.277。
KeyAI